新股消息 | 应世生物港股IPO招股书失效

Group 1 - InxMed Limited-B, also known as 应世生物, submitted its Hong Kong IPO application on August 25, 2025, which will expire on February 25, 2026 [1] - The company is a late-stage biotechnology firm established in 2017, focused on improving the efficacy of current cancer treatment options [2] - InxMed aims to address the core challenges of cancer treatment, particularly drug resistance caused by tumor defenses [2] Group 2 - The company focuses on key signaling pathways common across various tumor types, especially the FAK and integrin pathways, which play a critical role in tumor cell survival [2] - InxMed targets cancer-associated fibroblasts (CAFs) to dismantle the protective barriers surrounding tumor cells [2] - By targeting key pathways related to drug resistance, InxMed seeks to reshape rational drug use in cancer treatment and open new frontiers for therapeutic innovation [2]